A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial

Phase I ◽

Phase Ii Trial ◽

Controlled Trial ◽

Line Treatment ◽

First Line ◽

Randomized Controlled ◽

Randomized Phase Ii ◽

Abstract OT1-03-10: A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA-1 or -2 mutated Her2 negative advanced breast cancer as first line treatment (REVIVAL study)

10.1158/1538-7445.sabcs15-ot1-03-10 ◽

2016 ◽

Author(s):

GMHE Dackus ◽

PC Schouten ◽

JJ Geenen ◽

S Marchetti ◽

GS Sonke ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Brca 1 ◽

Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

Trials ◽

10.1186/s13063-016-1195-6 ◽

2016 ◽

Vol 17 (1) ◽

Author(s):

Denise A. Yardley ◽

Adam Brufsky ◽

Robert E. Coleman ◽

Pierfranco F. Conte ◽

Javier Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Controlled Trial ◽

Line Treatment ◽

First Line ◽

Randomized Controlled ◽

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

Trials ◽

10.1186/s13063-015-1101-7 ◽

2015 ◽

Vol 16 (1) ◽

Cited By ~ 18

Author(s):

Denise A. Yardley ◽

Adam Brufsky ◽

Robert E. Coleman ◽

Pierfranco F. Conte ◽

Javier Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Controlled Trial ◽

Line Treatment ◽

First Line ◽

Randomized Controlled ◽

A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial

Trials ◽

10.1186/s13063-016-1434-x ◽

2016 ◽

Vol 17 (1) ◽

Cited By ~ 20

Author(s):

Annika Karch ◽

Armin Koch ◽

Viktor Grünwald

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii Trial ◽

Controlled Trial ◽

Line Treatment ◽

First Line ◽

Advanced Soft Tissue Sarcoma ◽

Randomized Controlled ◽

595 EFFICACIES OF HYBRID, HIGH-DOSE DUAL AND BISMUTH QUADRUPLE THERAPIES IN THE FIRST-LINE TREATMENT OF H PYLORI INFECTION — A MULTICENTER RANDOMIZED CONTROLLED TRIAL

Gastroenterology ◽

10.1016/s0016-5085(21)01027-1 ◽

2021 ◽

Vol 160 (6) ◽

pp. S-115-S-116

Author(s):

Ping-I Hsu ◽

Jyh-Chin Yang ◽

Seng-Kee Chuah ◽

Kuan-Yang Chen ◽

Yu-Hwa Liu ◽

...

Keyword(s):

Controlled Trial ◽

High Dose ◽

Line Treatment ◽

First Line ◽

Randomized Controlled ◽

Multicenter Randomized Controlled Trial ◽

H Pylori ◽

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial.

10.1158/0008-5472.sabcs11-p5-19-03 ◽

2011 ◽

Cited By ~ 1

Author(s):

WJ Gradishar ◽

D Krasnojon ◽

S Cheporov ◽

AN Makhson ◽

GM Manikhas ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial

Medicine ◽

10.1097/md.0000000000013245 ◽

2018 ◽

Vol 97 (46) ◽

pp. e13245 ◽

Cited By ~ 2

Author(s):

Hyun Lim ◽

Chang Seok Bang ◽

Woon Geon Shin ◽

Jae Ho Choi ◽

Jae Seung Soh ◽

...

Keyword(s):

Helicobacter Pylori ◽

Controlled Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Quadruple Therapy ◽

Randomized Controlled ◽

Multicenter Randomized Controlled Trial ◽

Randomized phase II trial comparing docetaxel with or without low-dose metronomic oral cyclophosphamide in first-line treatment of non-triple-negative advanced breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.1041 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 1041-1041

Author(s):

Leiping Wang ◽

Jian Zhang ◽

Zhong Hua Wang ◽

Biyun Wang ◽

Jun Cao ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Low Dose ◽

Triple Negative ◽

Phase Ii Trial ◽

Oral Cyclophosphamide ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial

Trials ◽

10.1186/s13063-017-2281-0 ◽

2017 ◽

Vol 18 (1) ◽

Cited By ~ 4

Author(s):

Hyuk Lee ◽

◽

Beom Jin Kim ◽

Sang Gyun Kim ◽

Jin Il Kim ◽

...

Keyword(s):

Helicobacter Pylori ◽

Triple Therapy ◽

Study Protocol ◽

Controlled Trial ◽

Helicobacter Pylori Infection ◽

Line Treatment ◽

First Line ◽

Randomized Controlled ◽

Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Updated Results From the BICC-C Study

Journal of Clinical Oncology ◽

10.1200/jco.2007.15.5390 ◽

2008 ◽

Vol 26 (4) ◽

pp. 689-690 ◽

Cited By ~ 174

Author(s):

Charles S. Fuchs ◽

John Marshall ◽

José Barrueco

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Controlled Trial ◽

Line Treatment ◽

First Line ◽

Oral Fluoropyrimidines ◽

Randomized Controlled ◽